Medartis Sponsors First USA IBRA Symposium and Workshop
Medartis Selected as Sponsor for Symposium and Workshop to be Held in Miami
Importance of Real-Time CPR Feedback Presented at AHA Scientific Sessions 2009
ZOLL’s PocketCPR for iPhone Training App Debuts to Over 17,000 Downloads During AHA
-
-
Medtronic Receives International Business Leadership Award from the Greater Miami Chamber of Commerce
Medtronic, Inc. received today an International Business Leadership Award from the Greater Miami Chamber of Commerce in recognition for its significant impact on the economy of the state of Florida in the Education & Training category.
-
NIMS Receives Japanese Patent for Its Exer-Rest® Platform
Non-Invasive Monitoring Systems, Inc. [NIMS] (OTCBB:NIMU) announced that the Nogawa Patent Office in Japan issued Patent number 4391595 to NIMS on October 16, 2009. This patent, entitled “Reciprocating Movement Platform for Shifting Subject To and Fro In Headwards-Footwards Direction,” relates to the comprehensively researched technology underlying NIMS’ Exer-Rest acceleration therapeutic platform. This patent expires on March 18, 2018.
-
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution
Nutra Pharma has introduced Nyloxin OTC, an over-the-counter pain reliever, that will be marketed and sold through international distribution channels alongside the Company’s prescription pain reliever, Nyloxin Rx.
-
Novian Health Announces Agreement With Tower Radiology Center in Tampa Bay
Leading Radiology Practice Offers Novilase™ to Treat Breast Lumps
-
Results From Phase 2b Study on Atrial Fibrillation Agent Reviewed at American Heart Association
ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx’s compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida. The primary efficacy and safety results from PASCAL were announced in early 2009, demonstrating that budiodarone significantly reduces atrial fibrillation (AF) burden, or the time spent in AF, in patients suffering from paroxysmal AF. The details reviewed today focused on budiodarone’s rapid on-set of action, with a significant reduction in patients’ AF burden occurring within the first thirty days of treatment in two of three doses tested. In addition, the effect of budiodarone was sustained over the course of three months of treatment. Budiodarone is a novel oral antiarrythmic therapy modeled on the efficacy of amiodarone, the gold standard treatment for atrial fibrillation.
-
SafeStitch Medical, Inc. Receives FDA Clearance to Market the AMID StaplerTM for Hernia Repairs
SafeStitch Medical, Inc. (OTCBB:SFES) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its AMID StaplerTM in the U.S. with the intended use in general surgery procedures for fixation of mesh, in the repair of hernia defects and in other surgical specialties for the approximation of tissues, including skin. The AMID Stapler™ is the first surgical stapler designed specifically for use in inguinal hernia repairs using the Lichtenstein method, in which mesh is implanted to reinforce the groin floor. The Company has also applied for clearance to market the AMID StaplerTM in the European Economic Community and other areas outside of the U.S.
-
Celladon Corporation Announces Upcoming Presentations at American Heart Association Scientific Sessions 2009
Celladon Corporation, developing therapies for the treatment of heart failure, today announced upcoming data presentations at the American Heart Association (AHA) Scientific Sessions, November 14-18, 2009, Orlando, Florida.
-
Merck's Investigational Anacetrapib Phase IIb Study Results Presented at American Heart Association Annual Scientific Sessions
Persistent Lipid Effects Remained in the Higher Dose Arms After Cessation Of Therapy in Patients with Dyslipidemia
-
IVAX Diagnostics to Introduce MAGO 4 At MEDICA 2009 In Dusseldorf, Germany November 18 – 21, 2009
-- Enhancements Include ELISA and IFA Processing as Well as Increased Processing Capacity –-- Will Also Showcase New Simtomax Blood Drop Device --
-
Higher Dose of Merck’s COZAAR® (losartan potassium tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Study
Results from HEAAL Study Presented as Late-Breaker at American Heart Association Scientific Sessions 2009
-
Drug Therapy More Cost-Effective Than Angioplasty for Diabetic Patients with Heart Disease, Stanford Researcher Finds
Many patients with diabetes should forego angioplasties for heart disease and just take medicine instead, according to a new National Institutes of Health study led by Stanford University School of Medicine researcher Mark Hlatky, MD.
-
Quick-Med Technologies Receives First Royalties for its NIMBUS® Wound Dressings
Key Milestone in the Further Advancement of Patented NIMBUS TechnologyFinancial Results Reported Today on Form 10-Q
-
Patients at UCSD Hospital Three Times More Likely to Survive Cardiac Arrest with New Advanced Resuscitation Training Program
ZOLL Technology a Key Part of “Resuscitation Bundle” Improvement Report at AHA Resuscitation Science Symposium
-
Aegerion Pharmaceuticals Announces Additional Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Safety Profile
Results Will Be Presented Today At AHA Conference in Orlando, Florida
-
OPKO Health to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
OPKO Health, Inc. (NYSE Amex: OPK) today announced that senior management will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 4:40 PM EST. The conference will be held at the St. Regis Hotel in New York City.
-
GeneLink Reports Third Quarter Results
Revenues Exceed $2.1M
-
HyGreen Wins Popular Science’s 2009 “Best of What’s New” Award
Xhale Innovations, Inc. announced today that its hand hygiene system, HyGreen, is a recipient of the 2009 "Best of What's New" award from Popular Science magazine.
-
PanGenex Forms Exclusive Strategic Partnership with BulovaTech Labs
To Jointly Develop & Commercialize Patented Nutraceuticals
Marketplace
RSS|
My Yahoo|
Newsletters|
Widgets|
Mobile|
Alerts|
Twitter
Terms of Service| Privacy Policy| About our ads| Copyright| About The Miami Herald| About the McClatchy Company| Corrections| Contact Us| Advertise
Partners: El Nuevo Herald| Newspaper in Education| WLRN | Miami Herald News| CBS4 WFOR-TV| More
Copyright 2009 Miami Herald Media Co. All rights reserved